Table 1 Demographic and patient characteristics in treatment groups and controls
RA without DMARD (n = 50) | RA with MTX (n = 10) | pSS without DMARD (n = 15) | Controls (n = 49) | |
|---|---|---|---|---|
Age, median (range) years | 66.9 (35–87) | 67.4 (39–79) | 62.3 (25–89) | 57.2 (17–85) |
Sex (% female) | 78.0 | 70.0 | 87.0 | 63.3 |
Disease duration, mean (range) years | 5.6 (0–36) | 13.1 (2–40) | 7.0 (0–23) | – |
CRP, median (range) mg/L | 7 (0–78) | 3 (0–11) | 1.7 (0.7–38) | – |
ESR, median (range) mm/h | 21 (4–71) | 16 (5–42) | 12 (7–66) | – |
RF positive, % | 78 | 80 | 43 | – |
ACPA positive, % | 69 | 70 | 8 | – |
ANA positive, % | – | – | 73 | – |
Anti-ENA positive, % | – | – | 73 | – |
Anti-SSA (anti-Ro) positive, % | – | – | 67 | – |
Anti-SSB (anti-La) positive, % | – | – | 40 | – |
Prednisolone, % | 58 | 0 | 13 | 0 |
Dose, median (range) mg/day | 5 (0–15) | 0 | 0 (0–10) | – |
Previous PPV23, n (%): | 1 (2) | 0 | 0 | 3 (6) |